Monopar Therapeutics (MNPR) Net Cash Flow (QoQ) (2017 - 2025)
Monopar Therapeutics (MNPR) Net Cash Flow (QoQ) (2017 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Monopar Therapeutics | 707.36 Mn | 645.53 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -174.79% |
| Sep 30, 2025 | 42,712.70% |
| Jun 30, 2025 | 96.61% |
| Mar 31, 2025 | -115.34% |
| Dec 31, 2024 | 38,257.70% |
| Sep 30, 2024 | 93.83% |
| Jun 30, 2024 | -410.99% |
| Mar 31, 2024 | -69.12% |
| Dec 31, 2023 | 203.10% |
| Sep 30, 2023 | -214.24% |
| Jun 30, 2023 | 160.97% |
| Mar 31, 2023 | 59.72% |
| Dec 31, 2022 | -179.97% |
| Sep 30, 2022 | -57.84% |
| Jun 30, 2022 | 44.60% |
| Mar 31, 2022 | -21.79% |
| Dec 31, 2021 | -4.53% |
| Sep 30, 2021 | -36.44% |
| Jun 30, 2021 | -115.92% |
| Mar 31, 2021 | 819.90% |